Page 1

EX - 99.1 2 ptct - 20210729ex991e55f61.htm EX - 99.1 PTC / THERAPEUTICS ● TM - Total quarterly net revenue of $ 117 million ; 55 % increase over second quarter 2020 - Raises 2021 DMD franchise revenue guidance to $ 370- $ 390M from $ 355- $ 375M - - Progress across robust clinical pipeline with 3 ongoing registration - directed trials - SOUTH PLAINFIELD , N.J. , July 29 , 2021 - PTC Therapeutics , Inc. ( NASDAQ : PTCT ) today announced a corporate update and financial results for the second quarter ending June 30 , 2021 . PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results " I am delighted to say all facets of our business made substantial progress this quarter and we anticipate having four registration - directed trials ongoing by next quarter , " said Stuart W. Peltz , Ph.D. , Chief Executive Officer , PTC Therapeutics , Inc. “ I am also proud of the execution of the global commercial team , which is driving the continued robust growth of the DMD franchise and has led us to raise our 2021 revenue guidance despite ongoing challenges from the pandemic . " EXHIBIT 99.1 Key Second Quarter and Other Corporate Updates : The Duchenne muscular dystrophy ( DMD ) franchise had a total quarterly net product revenue of $ 102 million in the second quarter of 2021. This represents a 36 % growth over the second quarter of 2020 , continuing PTC's trend of strong quarterly commercial revenues . O O O O Emflaza® ( deflazacort ) revenue growth was primarily due to new patient starts , continued high adherence and fewer discontinuations . EvrysdiTM ( risdiplam ) received approval from the Ministry of Health Labor and Welfare in Japan in June 2021. Evrysdi is a product of a collaboration between PTC , Roche and the SMA Foundation . Translarna TM ( ataluren ) revenue growth was driven by expansion of the patient base , continued high compliance and broader access in existing geographies as well as continued geographic expansion including Russia , Central and Eastern Europe , Middle East and North Africa . Evrysdi is now approved in 54 countries . In the U.S. , more than 1800 patients are currently treated with Evrysdi , approaching 20 % total market share . Second Quarter Clinical Updates : The registration - directed Phase 3 PTC923 phenylketonuria ( PKU ) trial , APHENITY , is expected to initiate in the third quarter of 2021 . ● PTC has multiple ongoing clinical trials , three of which are registration - directed clinical studies : O The MIT - E Phase 2/3 vatiquinone trial for mitochondrial epilepsy with data anticipated in the third quarter of 2022 .